Fact CheckerSign in

NCT02775461Recruiting

Pancreas Registry and High Risk Registry

Pancreas Disease and High Risk Registry

Source: ClinicalTrials.gov · Last updated 11 Feb 2026

Brief summary (registry, in English)

The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of the pancreas, cystic lesions of the pancreas, and patients at high-risk of pancreatic cancer such as those with a family history of pancreatic cancer or with a family history of a syndrome known to be associated with pancreatic cancer. Pancreatic cancer is the fourth leading cause of death from cancer in the United States. However, little is known about the development of pancreatic cancer and pancreatic diseases in individuals with the above conditions. Knowledge of how family history, environmental exposures, and inflammatory lesion of the pancreas contribute to the development of pancreatic cancer and pancreatic diseases is essential. You may qualify to take part in this research study because you have inflammation in the pancreas, a pancreatic cyst, pre-cancerous lesions of the pancreas, pancreatic cancer, a family history of pancreatic cancer, or a family history of a syndrome known to be associated with pancreatic cancer. We will also be collecting a blood sample from all participants for DNA isolation. Sometimes we are born with genes or DNA that give us an increased or decreased chance of developing an illness later in life. Genetic material will be isolated from your blood for further study. You may also choose to provide additional blood samples for serum and plasma extraction. Serum and plasma are components of the blood which can be used to measure indicators of disease in the blood, called biomarkers,for pancreatic diseases. Clinical data and biological specimens contained in this study may be used for a wide variety of future related studies to the cause, diagnosis, outcome and treatment of pancreatic cancer. Funds for conducting this research are provided by Mount Sinai.

Status (registry)
Recruiting
Study type
Observational
Enrollment
1368 (estimated)
First submitted
13 May 2016
Start date
1 Mar 2013
Primary completion date
31 Jan 2033
Lead sponsor
Icahn School of Medicine at Mount Sinai
NCT number
NCT02775461

What you commit to

  • Study type: Observational
  • Planned participants: 1368
  • From 1 Mar 2013 to the primary completion date, 31 Jan 2033
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • Individuals under the age of 18 years

Other

  • Patients who do not speak English or Spanish
  • Refusal by patient

Who the study is looking for

  • At least 1 first degree relative affected with Pancreatic Cancer
  • Any of (BRCA1, BRCA2, PALB2, ATM) mutations + 1 family member with Pancreatic Cancer
  • mFAMMM (p16,CDKN2A mutations) + 1 family member with Pancreatic cancer
  • Known mutation carrier for STK11 (Peutz Jeghers Syndrome)
  • Lynch syndrome (HNPCC) + 1 family PDAC
  • Known mutation carrier for Hereditary pancreatitis
  • Individuals with a history of pancreatic cyst(s) (IPMN's) that measure ≥ 1 cm

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Mount Sinai West
Coordinator of this site? Confirm its status
New YorkUnited StatesRecruiting
Icahn School of Medicine at Mount Sinai
Coordinator of this site? Confirm its status
New YorkUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.